Actively Recruiting

Phase 2
Age: 1Year - 55Years
All Genders
NCT06943534

Omalizumab Weight-Based Dosing Efficacy Trial

Led by Massachusetts General Hospital · Updated on 2026-02-05

30

Participants Needed

3

Research Sites

143 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.

CONDITIONS

Official Title

Omalizumab Weight-Based Dosing Efficacy Trial

Who Can Participate

Age: 1Year - 55Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Positive skin prick test with a wheal 6 mm or larger to at least two relevant foods (peanut, cashew, walnut, egg, or milk)
  • Positive food-specific IgE level of 2.0 kUA/L or higher to at least two relevant foods
  • History of allergic reaction to at least one qualifying food other than the challenge food
  • Positive oral food challenge to one qualifying food at a cumulative dose of 144 mg or less (maximum tolerated dose 30 mg)
Not Eligible

You will not qualify if you...

  • Weight over 80 kg at screening
  • Clinically significant lab abnormalities at screening
  • Allergy or suspected allergy to omalizumab or its ingredients
  • Poorly controlled or severe asthma or wheezing at screening
  • History of severe anaphylaxis to study foods with neurological compromise or intensive care admission
  • Use of oral, IM, or IV steroids for more than 2 days (except for asthma/wheezing) within 30 days before screening
  • Current use of oral, IM, or IV corticosteroids, tricyclic antidepressants, or beta-blockers
  • Past or current eosinophilic gastrointestinal disease within 3 years
  • Past or current history of cancer or under investigation for cancer
  • Food immunotherapy within 6 months before screening
  • Monoclonal antibody or immunomodulatory therapy within 6 months before screening
  • Inability to stop antihistamines for required washout periods before tests
  • Pregnant, breastfeeding, or planning pregnancy during the study
  • Presence of clinically significant chronic disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

2

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

3

University of Texas Southwestern

Dallas, Texas, United States, 75390

Actively Recruiting

Loading map...

Research Team

J

Jannat Gill

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Omalizumab Weight-Based Dosing Efficacy Trial | DecenTrialz